Who is sponsoring NCT01253681?

NCT01253681 is sponsored by Amgen.

What condition does NCT01253681 study?

NCT01253681 studies Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer.

What drugs are being tested in NCT01253681?

Interventions: AMG 386, paclitaxel and carboplatin.

What is the status of NCT01253681?

NCT01253681 is currently COMPLETED.

Last reviewed 2015-10-13 · How we verify

A Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers

NCT01253681 Phase 1 COMPLETED

To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. The hypothesis is that AMG 386 in combination with carboplatin and paclitaxel is safe and well tolerated.

Details

Lead sponsor	Amgen
Phase	Phase 1
Status	COMPLETED
Enrolment	27
Start date	2010-11
Completion	2015-01

Conditions

Carcinoma
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions

AMG 386, paclitaxel and carboplatin

Primary outcomes

To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers. — 18 weeks of combination therapy

Countries

Australia, Belgium, Spain